- Conditions
- Severe Sepsis
- Interventions
- Talactoferrin alfa, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 27
- States / cities
- Loma Linda, California • Sacramento, California • Sylmar, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Recombinant Human Lactoferrin
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more
- Conditions
- Inflammation, Cognitive Deterioration
- Interventions
- rhLactoferrin, Placebo
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Clostridium Difficile
- Interventions
- recombinant human lactoferrin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Iron Deficiencies, Low Ferritin, Iron Deficiency, Exercise Performance of Fit Athletes
- Interventions
- Lactoferrin 100 mg, Lactoferrin 300 mg, Iron Supplementation (5 mg)
- Dietary Supplement
- Lead sponsor
- Lindenwood University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Immune Health
- Interventions
- High dose Human Lactoferrin, Low dose Human Lactoferrin, Active Control Bovine Lactoferrin
- Dietary Supplement
- Lead sponsor
- Midwest Center for Metabolic and Cardiovascular Research
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • Port Saint Lucie, Florida
- Conditions
- Nosocomial Infections
- Interventions
- Talactoferrin, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 1 Minute to 24 Hours
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Louisville, Kentucky • Columbia, Missouri
- Conditions
- HIV Infection
- Interventions
- Recombinant Lactoferrin, Placebo
- Drug
- Lead sponsor
- Jason Baker
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Talactoferrin, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • The Bronx, New York + 3 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Talactoferrin, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 29
- States / cities
- Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
- Conditions
- Exercise Performance
- Interventions
- Recombinant Bovine Lactoferrin, Bovine Milk-Derived Lactoferrin, Placebo
- Dietary Supplement
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 42 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
- Interventions
- talactoferrin, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Severe Sepsis
- Interventions
- Talactoferrin alfa, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more